Seeger Weiss Blog
Seeger Weiss Blog: Legal News and Analysis

Category : Fosamax

Fosamax Lawsuits On the Rise, Drug Injury Experts Warn of Fractures

November 8th, 2011

As lawsuits against Fosamax manufacturer, Merck & Co. emerge around the country, drug injury experts are warning patients and doctors about the drug’s harmful side effects. Most notably, the medication, which is indicated to strengthen the bones of those at risk for osteoporosis, has actually been said to make bones weaker, causing an array of unusual problems. Because of such claims, the FDA is expected to publish official warnings about Fosamax later this month. Sheryl Vondracek, an associate professor at the University of Colorado’s Department of Clinical Pharmacy cited in this article, notes that “osteoporosis of the jaw…has been reported with longer term use and atypical fractures, which are fractures of the femur, or thigh bone.”

The experienced drug injury attorneys of Seeger Weiss are actively investigating the claims of those who have been harmed by Fosamax. Click here to visit our Fosamax page.


Posted at 2:45 pm. No comments

Merck Faces Another Fosamax Drug Injury Suit

October 25th, 2011

In an Illinois circuit court, two women have filed a drug injury lawsuit against pharmaceutical giant, Merck Sharp & Dohme Corporation. Beth Tobias and Margaret Freiberg both took Fosamax, a drug manufactured by Merck to help prevent fractures in women with osteoporosis. However, both Tobias and Freiberg allege that Fosamax had the opposite effect on them, weakening their bones and actually increasing their risk of bone injury. Read the full story.

Calling on our experience in drug injury cases, including a $4.85 billion dollar settlement in a case involving another Merck drug, Vioxx, Seeger Weiss is currently taking on new Fosamax cases. Visit our Fosamax Investigation Page to learn more.


Posted at 2:35 pm. No comments

FDA Panels Recommend Clearer Fosamax Labels

September 19th, 2011

Fosamax, the subject of an ongoing Seeger Weiss investigation, is one of the four brands of bisphosphonates discussed in two advisory panels to the FDA on September 9. Bisphosphonates, drugs prescribed to women at risk of osteoporosis, have in recent years been demonstrated to cause fractures to the femur. Examining the mounting evidence, including the testimony of 18 victims who suffered atypical femoral fractures after taking the medication, the panels voted to recommend more specific instructions for how long Fosamax and other bisphosphonates should be used.

New York Times Article

Learn More about our Fosamax Investigation


Posted at 1:22 pm. No comments